Tech Company Inital Public Offerings
Ventyx Biosciences IPO
Ventyx Biosciences, operating out of Encinitas, offered its shares in an initial public offering on 10/21/2021.
Transaction Overview
Company Name
Announced On
10/21/2021
Transaction Type
IPO
Amount
$151,500,000
Proceeds Purpose
We currently intend to use the net proceeds from this offering to fund the clinical development of VTX958; to fund the clinical development of VTX002; to fund the clinical development of VTX2735; to fund research activities and preclinical development of our other development programs; and for business development activities, working capital needs and other general corporate purposes. We may also use a portion of our net proceeds to acquire, license or invest in complementary products, technologies, or businesses.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
662 Encinitas Blvd. 250
Encinitas, CA 92024
USA
Encinitas, CA 92024
USA
Phone
Undisclosed
Website
Email Address
Overview
We are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. Ventyx now includes combined assets from three separate companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting NLRP3 and the inflammasome, and Ventyx Biosciences, targeting TYK2.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 10/21/2021: Honeycomb venture capital transaction
Next: 10/21/2021: Flock Freight venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs